Genfit (GNFT) said late Tuesday it will receive a 26.5 million Euro ($29.9 million) milestone payment from Ipsen after Iqirvo's approval of pricing and reimbursement in Italy for Primary Biliary Cholangitis.
The payment milestone under the licensing and collaboration agreement with Ipsen will further support Genfit in advancing its pipeline for severe liver diseases, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.